Abstract: Owing to the rarity of deciduoid mesotheliomas, few studies have reported detailed morphological analyses. Here, we report a case of deciduoid mesothelioma along with cytological, histological, immunohistochemical, fluorescent in situ hybridization (FISH), and electron microscopic … More
Main Navigation Menu
➤ About the Law Offices of Thomas J. Lamb
PRACTICE AREAS
➤ Asbestos and Mesothelioma Claims
➤ Benzene Cancer and Disease Claims
➤ Pharmaceutical Drug Injury Lawsuits
➤ Breast Implants Lymphoma Cancer Lawsuits
➤ Free Case Evaluation by Lawyer Tom Lamb
INFORMATION
➤ Frequently Asked Questions (FAQs)
➤ Medical Records Copying Cost Laws
➤ Client Resources: Legal, Medical, and More
➤ Our "Recent Articles" Archives
To save time, you can use our Quick Contact Form to tell us about your possible case.
Recent Articles
Ozempic Warnings About NAION Eye-Injury Side Effect Still Missing as of July 2026
Numerous medical journal articles have been published in the past couple of years reporting an association between non-arteritic anterior ischemic optic neuropathy (NAION) and semaglutide, the active ingredient in Ozempic. As such, it is difficult to understand why Ozempic warnings about NAION as an … More
Wegovy and Ozempic Vision Loss Involving Semaglutide NAION Side Effect
There is an increasing number of lawsuits for Wegovy and Ozempic vision loss involving semaglutide-associated nonarteritic anterior ischemic optic neuropathy, commonly referred to as NAION or eye strokes. These semaglutide NAION lawsuits are based on the failure to warn about this serious side … More
NAION Cases Involve Mounjaro, Zepbound, Ozempic, and Wegovy, Other GLP-1 RAs
Nonarteritic anterior ischemic optic neuropathy, or NAION, cases involve Mounjaro, Zepbound, Ozempic, and Wegovy, as well as other glucagon-like peptide-1 receptor agonists (GLP-1RAs), according to an April 2026 medical study report published online by JAMA Network Open. This medical study … More
Tavneos Vanishing Bile Duct Syndrome Warning Addition to Drug Label
In late April 2026, Amgen announced a Tavneos vanishing bile duct syndrome warning addition to the Tavneos Prescribing Information document, or drug label, was submitted to the FDA for their consideration. This Amgen action came just two days after the FDA announced it was considering a Tavneos drug … More
Tavneos Drug Injury Cases Information From Lawyer Tom Lamb
In this post, we share some case criteria and law information for Tavneos drug injury cases that might be filed for patients with personal injury claims or families with wrongful death claims. We are investigating Tavneos drug injury cases involving people who developed a serious Tavneos … More